Point-of-Care Diagnostics Market Forecast to Reach $31.46 Billion by 2031

The drive toward decentralized healthcare is largely fueled by the rising prevalence of chronic conditions, including diabetes, cardiovascular issues, and respiratory illnesses. As healthcare systems prioritize early intervention and patient outcomes, the adoption of portable diagnostic platforms—ranging from blood glucose monitors to molecular testing kits—has become a cornerstone of modern clinical practice. Glucose monitoring products currently command the largest market share, bolstered by technological advancements in biosensors and cloud-integrated data management that simplify self-testing and glycemic control.

While home-based testing is expanding rapidly, clinical laboratories remain the primary end-users, leveraging high-volume diagnostic capacity to address infectious and cardiometabolic diseases. Geographically, the Asia Pacific region is expected to lead the global growth trajectory with an anticipated 11.1% CAGR. This surge is supported by significant investments in healthcare infrastructure and an aging population that requires more frequent, efficient screening. Industry leaders such as Abbott Laboratories, F. Hoffmann-La Roche, and Siemens Healthineers are currently positioning themselves to capture this shifting demand as diagnostic services move closer to the patient.